Entry limiting agreements: First‐mover advantage, authorized generics, and pay‐for‐delay deals-Reference-Cited by-同舟云学术

Entry limiting agreements: First‐mover advantage, authorized generics, and pay‐for‐delay deals

Published:2020-05-21 Issue:3 Volume:29 Page:516-542
ISSN:1058-6407
Container-title:Journal of Economics & Management Strategy
language:en
Short-container-title:J Econ Manage Strat

Author:

Bokhari Farasat A. S.¹²^ORCID,Mariuzzo Franco¹²,Polanski Arnold¹

Affiliation:

1. School of EconomicsUniversity of East Anglia Norwich UK

2. Centre for Competition PolicyUniversity of East Anglia Norwich UK

Publisher

Wiley

Subject

Management of Technology and Innovation,Strategy and Management,Economics and Econometrics,General Business, Management and Accounting,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jems.12351

Reference58 articles.

1. Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry

2. Barr Laboratories Inc.(August 14 2006).Barr and Shire sign three agreements: A product acquisition agreement for Adderall; a product development agreement; and a settlement and license agreement for Adderall XR. London UK: PR Newswire. (Press Release).

3. Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation

4. Authorized Generic Drugs, Price Competition, And Consumers’ Welfare

5. Strategic Deterrence of Sequential Entry into an Industry

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pay‐for‐delay with settlement externalities;The RAND Journal of Economics;2023-08-02

2. The Earlier the Better? Assessing Early Entry Agreements in the Pharmaceutical Sector;Journal of European Competition Law & Practice;2023-02-08